Nuvo Pharmaceuticals Revenue, Profits - NRIFF Quarterly Income Statement

Add to My Stocks
$2.12 $0.08 (3.92%) NRIFF stock closing price Sep 19, 2018 (Closing)

Fundamental analysis of NRIFF stock involves analyzing its financial statements, apart from checking the Nuvo Pharmaceuticals stock price. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue increase to $4.55M for 2018 Q2 impacts the NRIFF stock. Investors typically check year over year or quarter over quarter revenue growth. One also needs to look at Nuvo Pharmaceuticals assets, operating expenses and Nuvo Pharmaceuticals free cash flow. The Nuvo Pharmaceuticals profit and loss statement shows revenue of $4.55M for 2018 Q2. Revenue has grown by 29.63% QoQ for NRIFF stock.

View and download details of revenue and profits for Nuvo Pharmaceuticals for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Nuvo Pharmaceuticals Revenues or Net Sales
4.55M3.51M3.53M2.36M2.31M5.27M4.18M4.23M6.29M5.72M
Cost Of Goods Sold (COGS)--1.81M1.28M1.07M2.09M1.9M1.94M2.45M2.28M
Nuvo Pharmaceuticals Gross Profit
--1.79M1.06M1.22M3.18M2.3M2.28M3.83M3.43M
Research & Development Expense----------
Selling General & Admin Expense--1.86M1.15M1.22M1.26M-1.12M1.75M1.52M
Income Before Depreciation Depletion Amortization---0.12M-0.11M-0.13M1.68M1.2M-1.92M1.75M
Depreciation Depletion Amortization----------
Non Operating Income---0.01M-0.06M-0.01M-0.02M----0.34M
Interest Expense----------
Nuvo Pharmaceuticals Pretax Income
---0.11M-0.17M-0.15M1.65M1.31M-1.93M1.4M
Provision for Income Taxes----------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations--0.13M-0.15M-0.18M-0.15M1.66M1.3M-1.93M1.41M
Extraordinary Items & Discontinued Operations----------2.32M
Nuvo Pharmaceuticals Profit/ Loss (Net Income)
--0.13M-0.15M-0.18M-0.15M1.66M1.3M-1.93M-0.91M
Average Shares used to compute Diluted EPS11.47M11.58M11.72M11.55M11.55M11.76M11.46M11.81M11.76M11.5M
Average Shares used to compute Basic EPS11.41M11.58M11.72M11.55M11.55M11.55M11.46M11.5M11.49M11.3M
Income Before Nonrecurring Items---0.15M-0.18M-0.15M1.66M1.3M-1.93M1.41M
Income from Nonrecurring Items--0.31M--------
Nuvo Pharmaceuticals Earnings Per Share Basic Net
0.07-0.01-0.02-0.02-0.020.140.110.080.17-0.08
Nuvo Pharmaceuticals Earnings Per Share Diluted Net
0.07-0.01-0.02-0.02-0.020.140.110.070.16-0.08
EPS Diluted Before Nonrecurring Items0.070.02-0.02-0.02-0.020.140.110.070.160.11
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Click here to view our Novartis financial analysis

It is very helpful to read a report on Nuvo Pharmaceuticals stock analysis. An investor must check the following items in an income statement:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $4.55M for this quarter of 2018 Q2. Our Nuvo Pharmaceuticals revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: Most businesses like Nuvo Pharmaceuticals try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called statement of revenue and expense. The NRIFF financials along with Nuvo Pharmaceuticals historical stock prices provide a lot of details about the firm.

Nuvo Pharmaceuticals Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
106.05
PS Ratio (price sales ratio)
1.73
Operating Margin
0
Net Profit Margin
18
Dividend Yield
0%